Patents by Inventor Reza Mazhari
Reza Mazhari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257363Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: September 23, 2022Publication date: August 17, 2023Inventors: Reza Mazhari, Djelila Mezaache, Blake M Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 11479542Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: May 27, 2020Date of Patent: October 25, 2022Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20210107892Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: May 27, 2020Publication date: April 15, 2021Inventors: Reza Mazhari, Ojelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20200231553Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 21, 2020Publication date: July 23, 2020Applicant: REXAHN PHARMACEUTICALS, INC.Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
-
Patent number: 10710976Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: February 11, 2019Date of Patent: July 14, 2020Assignees: Cerecor Inc., Merck Sharp & Dohme Corp.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 10570101Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 6, 2018Date of Patent: February 25, 2020Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
-
Publication number: 20190275042Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: ApplicationFiled: March 18, 2019Publication date: September 12, 2019Applicant: Rexahn Pharmaceuticals, Inc.Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
-
Publication number: 20190177299Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: February 11, 2019Publication date: June 13, 2019Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 10278971Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: GrantFiled: August 22, 2017Date of Patent: May 7, 2019Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
-
Patent number: 10202363Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: December 18, 2015Date of Patent: February 12, 2019Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20180290985Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 6, 2018Publication date: October 11, 2018Applicant: REXAHN PHARMACEUTICALS, INC.Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
-
Patent number: 9969698Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 2, 2016Date of Patent: May 15, 2018Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
-
Publication number: 20180021338Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: ApplicationFiled: August 22, 2017Publication date: January 25, 2018Applicant: Rexahn Pharmaceuticals, Inc.Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
-
Publication number: 20170369469Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: December 18, 2015Publication date: December 28, 2017Applicants: Cerecor, Inc., Merck Sharp & Dohme Corp.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 9782410Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: GrantFiled: June 9, 2016Date of Patent: October 10, 2017Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
-
Publication number: 20170066726Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 2, 2016Publication date: March 9, 2017Applicant: REXAHN PHARMACEUTICALS, INC.Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
-
Publication number: 20170014411Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: ApplicationFiled: June 9, 2016Publication date: January 19, 2017Applicant: Rexahn Pharmaceuticals, Inc.Inventors: Young Bok Lee, Deog Joong Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
-
Publication number: 20160081951Abstract: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 24, 2015Publication date: March 24, 2016Inventors: Reza Mazhari, Vincent J. Kalish
-
Publication number: 20130274342Abstract: Compositions, methods of making compositions and methods of treating cough are described herein. In some embodiments, the compositions are lozenges comprising memantine and an alkalinizing agent.Type: ApplicationFiled: March 14, 2013Publication date: October 17, 2013Applicant: Cerecor, Inc.Inventors: Mark GINSKI, Blake PATERSON, Reza MAZHARI, Djelila MEZAACHE
-
Publication number: 20110160200Abstract: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 22, 2010Publication date: June 30, 2011Applicant: CARDIOXYL PHARMACEUTICALS, INC.Inventors: Reza Mazhari, Vincent J. Kalish